Table 1. Clinical trials reported for drugs that target IFN-γ/CXCL10 pathway.
| Target | Compound | Company | Phase | Indication | Design | Status |
|---|---|---|---|---|---|---|
| IFN-γ | AMG 811 | Amgen | I | SLE | Safety study, randomized, double-blind, placebo-controlled | Completed, acceptable safety, not designed to study clinical efficacy, dose-dependent reduction in serum CXCL10 |
| AMG 811 | Amgen | I | DLE | Safety/efficacy study, randomized, double-blind, placebo-controlled | Terminated, acceptable safety, no apparent clinical efficacy, pharmacodynamic efficacy in blood but not in skin | |
| AMG 811 | Amgen | I | Psoriasis | Safety study, randomized, double-blind, placebo-controlled | Completed, study results not reported | |
| Fontolizumab | PDL BioPharma | II | RA | Efficacy study, randomized, open-label | Terminated early because the first phase did not meet the primary endpoint | |
| Fontolizumab | Facet Biotech | I | CD | Safety/efficacy study, randomized, double-blind, placebo-controlled | Completed, well tolerated, but did not meet the primary clinical endpoint | |
| NI-0501 | NovImmune | II | HLH | Safety/efficacy study, open-label, single-arm | Currently recruiting participants | |
| CXCR3 | AMG 487 | Amgen-Tularik | II | Psoriasis | Safety/efficacy study, randomized, double-blind, placebo-controlled | Terminated due to the lack of efficacy |
| CXCL10 | BMS-936557 | Bristol-Myers; squibb | II | RA | Efficacy study, randomized, double-blind, placebo-controlled, multi-dose | Completed, well tolerated, met the primary clinical efficacy endpoint |
| BMS-936557 | Bristol-Myers; squibb | II | UC | Safety/efficacy study, randomized, double-blind, placebo-controlled, multi-dose | Completed, well tolerated, modest clinical efficacy, but did not meet the primary or secondary endpoints | |
| BMS-936557 | Bristol-Myers; squibb | II | CD | Safety/efficacy study, randomized, double-blind, placebo-controlled | Completed, study results not reported | |
| NI-0801 | NovImmune | II | PBC | Safety/efficacy study, open-label, single-arm, multiple-dose | Terminated, study results not reported |
SLE, systemic lupus erythematosus; DLE, discoid lupus erythematosus; RA, rheumatoid arthritis; CD, Crohn’s disease; HLH, hemophagocytic lymphohistiocytosis; UC, ulcerative colitis; PBC, primary biliary cirrhosis.